AstraZeneca PLC (AZN)
NASDAQ: AZN · Real-Time Price · USD
77.69
+0.13 (0.17%)
At close: Sep 17, 2025, 4:00 PM EDT
77.58
-0.11 (-0.14%)
After-hours: Sep 17, 2025, 7:59 PM EDT
AstraZeneca Revenue
AstraZeneca had revenue of $14.46B in the quarter ending June 30, 2025, with 11.74% growth. This brings the company's revenue in the last twelve months to $56.50B, up 15.00% year-over-year. In the year 2024, AstraZeneca had annual revenue of $54.07B with 18.03% growth.
Revenue (ttm)
$56.50B
Revenue Growth
+15.00%
P/S Ratio
4.27
Revenue / Employee
$608,192
Employees
92,900
Market Cap
241.43B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 54.07B | 8.26B | 18.03% |
Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
Thermo Fisher Scientific | 43.21B |
AZN News
- 13 hours ago - AstraZeneca's Fasenra Falls Short In Smoker's Lung Trial - Benzinga
- 20 hours ago - SAPHNELO self-administration TULIP-SC Phase III trial meets primary endpoint in patients with systemic lupus erythematosus based on an interim analysis - Business Wire
- 1 day ago - AstraZeneca's asthma drug fails main goal of COPD study - Reuters
- 2 days ago - AstraZeneca Puts Cambridge Expansion On Ice Adding Pressure On Starmer Ahead Of Trump Visit - Benzinga
- 2 days ago - AstraZeneca shares down 3% after rating cut, UK investment pause - Reuters
- 2 days ago - AstraZeneca Pauses Plans for $271 Million Expansion of U.K. Site - WSJ
- 5 days ago - AstraZeneca pauses £200mn Cambridge investment amid UK pharma uncertainty - Invezz
- 5 days ago - Exclusive: AstraZeneca pauses $270 million investment in Britain - Reuters